Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of recombinant zoster vaccination and tofacitinib initiation in rheumatoid arthritis
jRCTs031230329Completed
- Sponsor
- Pfizer
- Start
- Sep 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tofacitinib and Zoster vaccine recombinant in rheumatoid arthritis (RA) and herpes zoster (HZ), sponsored by Pfizer. Primary endpoint: Within-group change in VZV-specific IgG antibody titers. Started Sep 2023; status: completed.
02
Drugs
tofacitinibZoster vaccine recombinant
03
Conditions
rheumatoid arthritis (RA)herpes zoster (HZ)
Beyond the preview
Go deeper on jRCTs031230329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230329.